Table 1.
Patient Characteristics
| Characteristic | Prepandemic Year (2019-2020) | Pandemic Year (2020-2021) |
|---|---|---|
| Sex | ||
| Female | 59 (54) | —a |
| Male | 51 (46) | —a |
| Age, y | ||
| 18-24 | 27 (25) | —a |
| 25-34 | 41 (37) | —a |
| 35-44 | 19 (17) | —a |
| 45-54 | 15 (14) | —a |
| 55+ | 8 (7) | —a |
| Ethnicity | ||
| White | 105 (95) | —a |
| Black | 5 (5) | —a |
| Hispanic | 0 | —a |
| Genetics | ||
| del F508 homozygous | 59 (54) | —a |
| del F508 heterozygous | 40 (36) | —a |
| Lung function, FEV1 % predicted | ||
| < 40% | 17 (15) | 15 (14) |
| 40%-69% | 30 (27) | 29 (26) |
| 70%-89% | 39 (35) | 35 (32) |
| > 90% | 24 (22) | 31 (28) |
| Pulmonary exacerbations per year | ||
| Total exacerbations | 96 | 38 |
| Annualized exacerbations per person | 0.13 | 0.05 |
| CFTR modulator use | ||
| Elexacaftor/tezacaftor/ivacaftor | 88 (80) | 94 (85) |
| Tezacaftor/ivacaftor | 55 (50) | 2 (2) |
| Lumacaftor/ivacaftor | 7 (6) | 2 (2) |
| Ivacaftor | 17 (15) | 4 (4) |
| Microbiology of colonizing species | ||
| P. aeruginosa | 66 (60) | 52 (47) |
| Methicillin-resistant S. aureus | 28 (25) | 25 (22) |
| S. maltophilia | 19 (18) | 13 (12) |
| B. cepacia complex | 5 (4) | 4 (3) |
| Aspergillus | 40 (37) | 14 (13) |
| Achromobacter | 10 (9) | 7 (6) |
| Nontuberculous mycobacterium | 23 (21) | 9 (8) |
| CF-related diabetes | ||
| Yes | 41 (37) | 45 (41) |
| Negative screening during calendar year | 38 (35) | 28 (25) |
| Not screened during calendar year | 31 (28) | 37 (34) |
| CF bone disease | ||
| Screened and normal | 43 (39) | 50 (45) |
| Osteopenia | 33 (30) | 40 (36) |
| Osteoporosis | 3 (3) | 5 (5) |
| Unknown | 31 (28) | 15 (14) |
| BMI, kg/m2 | ||
| ≤ 17 | 3 (3) | 3 (3) |
| 18-23 | 51 (46) | 38 (35) |
| ≥ 24 | 56 (51) | 69 (62) |
Data are presented as No. (%) or No. CF = cystic fibrosis; CFTR = cystic fibrosis transmembrane conductance regulator.
a
Data only collected for the baseline year for this characteristic.